NALOXONE HYDROCHLORIDE (AUTOINJECTOR) Drug Patent Profile

Which patents cover Naloxone Hydrochloride (autoinjector), and when can generic versions of Naloxone Hydrochloride (autoinjector) launch?

Naloxone Hydrochloride (autoinjector) is a drug marketed by Kaleo Inc and is included in one NDA. There are six patents protecting this drug.

This drug has thirty-five patent family members in ten countries.

The generic ingredient in NALOXONE HYDROCHLORIDE (AUTOINJECTOR) is naloxone hydrochloride. There are twelve drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Naloxone Hydrochloride (autoinjector)

A generic version of NALOXONE HYDROCHLORIDE (AUTOINJECTOR) was approved as naloxone hydrochloride by HOSPIRA on September 24^th, 1986.

Summary for NALOXONE HYDROCHLORIDE (AUTOINJECTOR)

International Patents:	35
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NALOXONE HYDROCHLORIDE (AUTOINJECTOR)
DailyMed Link:	NALOXONE HYDROCHLORIDE (AUTOINJECTOR) at DailyMed

Recent Clinical Trials for NALOXONE HYDROCHLORIDE (AUTOINJECTOR)

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Purdue Pharma LP	PHASE1
Pfizer	Phase 1
National Institute on Drug Abuse (NIDA)	Phase 1

See all NALOXONE HYDROCHLORIDE (AUTOINJECTOR) clinical trials

Pharmacology for NALOXONE HYDROCHLORIDE (AUTOINJECTOR)

Drug Class	Opioid Antagonist
Mechanism of Action	Opioid Antagonists

US Patents and Regulatory Information for NALOXONE HYDROCHLORIDE (AUTOINJECTOR)

NALOXONE HYDROCHLORIDE (AUTOINJECTOR) is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kaleo Inc	NALOXONE HYDROCHLORIDE (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	215457-001	Feb 28, 2022		DISCN	Yes	No
Kaleo Inc	NALOXONE HYDROCHLORIDE (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	215457-001	Feb 28, 2022		DISCN	Yes	No			Y
Kaleo Inc	NALOXONE HYDROCHLORIDE (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	215457-001	Feb 28, 2022		DISCN	Yes	No
Kaleo Inc	NALOXONE HYDROCHLORIDE (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	215457-001	Feb 28, 2022		DISCN	Yes	No			Y
Kaleo Inc	NALOXONE HYDROCHLORIDE (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	215457-001	Feb 28, 2022		DISCN	Yes	No			Y
Kaleo Inc	NALOXONE HYDROCHLORIDE (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	215457-001	Feb 28, 2022		DISCN	Yes	No			Y

Expired US Patents for NALOXONE HYDROCHLORIDE (AUTOINJECTOR)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kaleo Inc	NALOXONE HYDROCHLORIDE (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	215457-001	Feb 28, 2022
Kaleo Inc	NALOXONE HYDROCHLORIDE (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	215457-001	Feb 28, 2022
Kaleo Inc	NALOXONE HYDROCHLORIDE (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	215457-001	Feb 28, 2022
Kaleo Inc	NALOXONE HYDROCHLORIDE (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	215457-001	Feb 28, 2022
Kaleo Inc	NALOXONE HYDROCHLORIDE (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	215457-001	Feb 28, 2022
Kaleo Inc	NALOXONE HYDROCHLORIDE (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	215457-001	Feb 28, 2022
Kaleo Inc	NALOXONE HYDROCHLORIDE (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	215457-001	Feb 28, 2022

International Patents for NALOXONE HYDROCHLORIDE (AUTOINJECTOR)

See the table below for patents covering NALOXONE HYDROCHLORIDE (AUTOINJECTOR) around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2012103316
United Kingdom	2471981	Medicament delivery device having an electronic circuit system
Japan	2011519712
Canada	2594627	DISPOSITIFS, SYSTEMES ET PROCEDES POUR ADMINISTRER UN MEDICAMENT (DEVICES, SYSTEMS, AND METHODS FOR MEDICAMENT DELIVERY)
World Intellectual Property Organization (WIPO)	2007126851
United Kingdom	201316340
Canada	2825637	DISPOSITIFS ET PROCEDES PERMETTANT DE FOURNIR DES MEDICAMENTS A PARTIR D'UN RECIPIENT A CHAMBRES MULTIPLES (DEVICES AND METHODS FOR DELIVERING MEDICAMENTS FROM A MULTI-CHAMBER CONTAINER)

Supplementary Protection Certificates for NALOXONE HYDROCHLORIDE (AUTOINJECTOR)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1685839	92292	Luxembourg		PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE

Market Dynamics and Financial Trajectory for NALOXONE HYDROCHLORIDE (AUTOINJECTOR)

Last updated: January 3, 2026

---

Executive Summary

Naloxone Hydrochloride Autoinjectors have emerged as pivotal tools in combating opioid overdose crises worldwide. The shift from traditional nasal sprays and injectable formats to autoinjector devices signifies an evolution geared towards ease of use, rapid administration, and increased adoption in emergency settings, including by laypersons. The global market for naloxone autoinjectors is projected to grow substantially, driven by increasing opioid overdose mortality, regulatory approvals, and expanding distribution networks. This article provides a comprehensive analysis of the market dynamics, financial landscape, key players, regulatory environment, and future outlook in this fast-evolving sector.

---

What Are Naloxone Hydrochloride Autoinjectors?

Definition:
Naloxone Hydrochloride autoinjectors are prefilled, single-use devices designed to deliver a potent opioid antagonist rapidly, reversing life-threatening opioid overdoses. The user activates the device, which then autonomously injects the medication into muscle tissue, typically thigh or arm.

Key features:

• Ease of administration: Designed for non-medical personnel.
• Rapid action: Onset within minutes.
• Portability: Compact, suitable for emergency kits.
• Regulatory approval: Approved across various countries, including FDA approval in the U.S. (e.g., Evzio, marketed by Kaleo) and CE marking in Europe.

---

Market Drivers

Driver	Description	Impact
Ongoing Opioid Crisis	Increasing overdose deaths, especially in North America and Europe. US CDC reports over 100,000 overdose deaths annually, with opioids responsible for approx. 70% [1].	Propels demand for accessible naloxone delivery systems.
Regulatory Approvals & Policies	Agencies such as FDA expand access to naloxone autoinjectors, including over-the-counter (OTC) status and state-level standing orders.	Broadens market reach and facilitates purchase for lay users.
Public and First Responder Adoption	EMTs, police, and community programs increasingly equipped with autoinjectors.	Drives volume sales and normalizes use.
Innovation in Autoinjector Technology	Development of user-friendly devices with features like voice guidance and minimal training requirements.	Enhances user engagement and adherence.
Insurance & Reimbursement Expansion	Insurance companies and Medicaid programs including naloxone autoinjectors in coverage plans.	Improves affordability and accessibility, encouraging distribution.

---

Market Restraints & Challenges

Restraint	Description	Mitigation Strategies
High Cost of Devices	Autoinjectors retail at $400-$800, compared to nasal sprays at ~$100.	Insurance coverage expansion; manufacturing cost reductions.
Limited Awareness & Training	Lack of widespread knowledge on emergency use impacts adoption.	Educational campaigns, community outreach.
Supply Chain Disruptions	External factors like COVID-19 have impacted manufacturing and distribution.	Diversification of manufacturing sources.
Patent & Competitive Dynamics	Patent expirations may lead to generic alternatives, affecting pricing.	Focus on device innovation and patent protections.

---

Key Players & Product Landscape

Company	Product	Features	Market Share	Notes
Kaleo (Acquired by Teva)	Evzio	Auto-injector, voice-guided, FDA-approved	Significant initial share	Now integrated into Teva's portfolio
Adapt Pharma (Emergent BioSolutions)	Narcan (Auto-injector & nasal spray)	Widely distributed, OTC approval in some markets	Leading market share globally	First FDA-approved naloxone auto-injector
Emergex (Evolution in Device Design)	FirstResponder	User-friendly, smartphone integration	Niche but growing	Focused on technological innovation
Hightide Therapeutics & Others	Generic auto-injectors	Cost-effective, competition increasing	Market penetration rising	Emphasis on affordability

---

Regulatory Landscape and Policy Frameworks

Region	Regulatory Status	Key Policies	Impact on Market
United States	FDA-approved (Evzio, Auvi-Q)	State standing orders, OTC options	Rapid expansion in availability
Europe	CE Mark approved	National subsidy programs	Growing adoption in healthcare systems
Canada	Health Canada approvals	Distribution via pharmacies	Increasing public access
Australia & Asia	Regulatory approvals	Pilot programs	Emerging opportunities

Policy Initiatives:

• US: The HHS launched the Overdose Prevention Strategy emphasizing widespread naloxone distribution.
• EU: The European Monitoring Centre for Drugs and Drug Addiction advocates for harm reduction policies, including naloxone availability.

---

Financial Trajectory & Market Forecasts

Current Market Size

Metric	2022 Estimate	Notes
Global Market Value	~$750 million	Primarily North America, expanding in Europe, Asia-Pacific
Units Sold	~3 million autoinjectors	Rapid growth trajectory

Projected Growth & Outlook

Year	Estimated Market Value	CAGR (2023–2030)	Assumptions
2023	~$850 million	12%	Regulatory expansions & innovation
2025	~$1.2 billion	15%	Increased adoption outside North America
2030	~$2.5 billion	20%	Global proliferation & OTC availability

Sources: Industry analyst reports (e.g., Grand View Research, MarketsandMarkets).

Revenue Drivers & Topline Factors

Factor	Contribution	Estimated Impact
Device Pricing Trends	Decreasing due to generics	Margins compressed but volume rises
Reimbursement Policies	Broadening coverage	Increased sales volume
Distribution Expansion	Public programs, EMS	Accelerates market penetration
Device Innovation	Enhanced features	Justifies premium pricing temporarily

---

Competitive Intelligence & Comparative Analysis

Aspect	Evzio	Narcan Auto-injector	Hightide & Generics
FDA Status	Approved	Approved	Approved or pending
Pricing	~$600	~$400	~$100–$200
Ease of Use	Voice-guided	User-driven	Varies
Market Penetration	Limited but substantial	Leading	Growing rapidly
Distribution Channels	Hospitals, EMS, pharmacies	Pharmacies, OTC	Pharmacies, online

Key differentiation factors: device usability, pricing, regulatory status, and distribution channels.

---

Future Outlook: Opportunities and Risks

Opportunities	Risks
Emergence of OTC market	Regulatory delays or restrictions
Partnerships with public health organizations	Price wars and insurrections in pricing strategies
Technological advances	Patent expirations leading to commoditization
Global expansion	Market saturation in North America

---

Conclusion: Strategic Insights

The naloxone autoinjector market is poised for robust growth, driven by the escalating opioid overdose crisis and supportive regulatory frameworks. Companies innovating in device design, improving affordability, and expanding public access will shape the competitive landscape. Strategic partnerships with governments and non-profits, combined with a focus on education and training, are essential for capturing market share. Additionally, the transition toward OTC status in multiple jurisdictions represents a pivotal opportunity to facilitate widespread use and generate sustained revenue streams.

---

Key Takeaways

• Market Growth: Expected CAGR of 15–20% from 2023 to 2030, reaching ~$2.5 billion globally.
• Cost & Accessibility: Price sensitivity remains a concern; generics and reimbursement policies are crucial.
• Regulatory Developments: Broader OTC approvals and standing orders will expand access.
• Innovation & Differentiation: Enhanced user-centric features and technological integration can drive competitive advantage.
• Global Opportunity: Markets beyond North America, especially Asia-Pacific and Europe, are emerging growth areas.

---

FAQs

1. What are the primary competitive advantages of naloxone autoinjectors over nasal sprays?
Autoinjectors offer rapid, one-handed administration, higher certainty of delivery, and reduced user error, especially in high-stress overdose scenarios. They are particularly advantageous in emergency settings where quick action is vital.

2. How do pricing and reimbursement affect the adoption of naloxone autoinjectors?
High retail prices hinder access for underserved populations. Reimbursement policies, including Medicaid coverage and government subsidies, significantly influence distribution and public health impact.

3. What is the impact of patent expirations on the market?
Patent expirations of branded autoinjectors lead to increased generic competition, reducing prices and expanding access. Companies investing in device innovation can sustain competitive edges despite patent expiries.

4. How will regulatory policies influence future market expansion?
Broader OTC approvals, standing orders, and government distribution programs will lower barriers, increase accessibility, and ultimately drive market growth.

5. What are the key risks preventing market growth?
Pricing pressures, regulatory delays, supply chain disruptions, and potential public stigma around opioid use can impede growth trajectories.

---

References

[1] Centers for Disease Control and Prevention (CDC), "Opioid Overdose Data," 2022.
[2] Grand View Research, "Naloxone Market Analysis," 2022.
[3] MarketsandMarkets, "Pharmaceutical Auto-injector Market," 2022.
[4] U.S. Food and Drug Administration (FDA), "Naloxone Auto-Injectors," 2018.
[5] European Monitoring Centre for Drugs and Drug Addiction, "Harm Reduction Strategies," 2021.

---

This report aims to inform stakeholders and decision-makers seeking a detailed understanding of the pharmaceutical landscape surrounding naloxone autoinjectors, emphasizing strategic avenues for growth and risk management.